In the field of pharmaceutical and medical device regulation in the EU, power is increasingly moving from member states to Brussels. This is largely a good thing for the life sciences industry as it will make Europe more competitive internationally.
This article was published in the August 2013 issue of Scrip Regulatory Affairs.